TGFB1 and neoplasm: Bi-specific compounds that target the LAP/TGFβ complex-binding site of both αvβ6 and αvβ8 integrins may represent, therefore, not only useful ligands for drug delivery to tumors but also important tumor-homing inhibitors of TGFβ-mediated immunosuppressive mechanisms.